Literature DB >> 3531126

Treatment of Streptococcus agalactiae mastitis in dairy cows: comparative efficacies of two antibiotic preparations and factors associated with successful treatment.

L D Weaver, J Galland, P A Martin, J Versteeg.   

Abstract

A commercially available, penicillin-novobiocin, intramammary infusion product and a solution of procaine penicillin G (1.2 X 10(6) IU) in 10 ml of sterile saline solution were evaluated for their comparative efficacies against Streptococcus agalactiae mastitis in 3 California dairy herds. After composite milk samples from each cow in each herd were bacteriologically cultured, cows infected with S agalactiae (n = 228) were assigned randomly to 2 treatment groups. Milk samples were reevaluated bacteriologically 21 to 25 days after treatment. Both preparations were highly effective against S agalactiae in first-lactation cows and in cows scored negative or trace by use of the California Mastitis Test. Efficacy was significantly decreased in cows with California Mastitis Test scores of 1, 2, or 3. Herd and treatment were associated significantly with treatment success or failure. Most treatment failures were in one herd in cows that were given procaine penicillin G in sterile saline solution. Milk production and lactation stage were not associated with success or failure of treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3531126

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  2 in total

Review 1.  Streptococcus agalactiae mastitis: a review.

Authors:  G P Keefe
Journal:  Can Vet J       Date:  1997-07       Impact factor: 1.008

2.  Efficacy of cefquinome and a combination of cloxacillin and ampicillin for treatment of dairy cows with Streptococcus agalactiae subclinical mastitis.

Authors:  Rodolfo Santos Rossi; Ariadne Ferreira Amarante; Simony Trevisan Guerra; Giulia Soares Latosinski; Bruna Fernanda Rossi; Vera Lucia Mores Rall; Jose Carlos de Figueiredo Pantoja
Journal:  PLoS One       Date:  2019-04-25       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.